FDA Approves Avsola, Remicade Biosimilar, to Treat Active Ankylosing Spondylitis
The U.S. Food and Drug Administration (FDA) has approved Avsola (infliximab-axxq), a biosimilar to Remicade (infliximab), to treat active ankylosing spondylitis, its maker, Amgen, announced. The new therapy has been approved across all diseases that Remicade can treat, which in addition to active ankylosing spondylitis are moderate-to-severe rheumatoid arthritis,…